EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, published by the American Psychological Association, stands as a pivotal resource within the fields of pharmacology and psychiatry. With an ISSN of 1064-1297 and an E-ISSN of 1936-2293, this journal contributes significantly to the understanding of psychopharmacological interventions through its rich array of research articles, reviews, and clinical studies. Classified within the Q2 category in both Pharmacology and Psychiatry and Mental Health, it reflects a solid standing in academic performance, evidenced by its rankings in Scopus, where it places within the top half of its categories. Spanning from 1993 to 2024, it seeks to provide an essential platform for the dissemination of knowledge and advancements that influence clinical practice and therapeutic approaches. Although not an open-access journal, its impact on the development of evidence-based psychopharmacological treatments cannot be overstated, making it a vital resource for researchers, clinically active professionals, and students eager to stay abreast of cutting-edge developments in mental health and pharmacology.

ACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

Journal of Child and Adolescent Psychiatric Nursing is a vital resource for those engaged in the fields of nursing, psychiatry, and pediatrics, dedicated to the advance of knowledge surrounding the mental health needs of children and adolescents. Published by WILEY, this peer-reviewed journal, with ISSN 1073-6077 and E-ISSN 1744-6171, has built a reputation for excellence since its inception in 1988 and continues to contribute significant insights through 2024. The journal holds an impressive Q1 ranking in Pediatrics and a Q2 ranking in Medicine (miscellaneous), underscoring its impact within these critical areas. Enhancing its relevance, it ranks #12/25 in Nursing - Pediatrics and #17/45 in Nursing - Psychiatric Mental Health, highlighting its important niche. Although it currently does not offer open access, the journal remains essential for researchers, clinicians, and students focusing on the complexities of mental health nursing for younger populations, ultimately aiming to improve care strategies and outcomes. Discover compelling research and discussions that shape the future of psychiatric nursing practice, promoting the well-being of children and adolescents.

Journal of the Canadian Academy of Child and Adolescent Psychiatry, published by the esteemed Canadian Academy of Child & Adolescent Psychiatry, serves as a crucial platform for scholarly discourse in the fields of Pediatrics and Psychiatry. With an ISSN of 1719-8429, this journal has been significantly contributing to the advancement of knowledge from 2006 to 2024, achieving notable recognition as a Q2 journal in both Pediatrics, Perinatology and Child Health, and Psychiatry and Mental Health categories. The journal's current Scopus rankings reflect its quality, sitting at the 70th percentile in Pediatrics and the 55th percentile in Psychiatry. Though currently not an open access journal, it provides valuable insights, research findings, and clinical implications for researchers, clinicians, and students dedicated to child and adolescent mental health. Its location in Canada underscores a commitment to advancing healthcare and mental wellness for young populations through rigorous academic inquiry.

CNS DRUGS is a leading journal dedicated to the field of neuroscience, specifically focused on the advancement of pharmacological therapies for central nervous system disorders. Published by ADIS INT LTD, this esteemed journal has maintained a strong impact within its domain, achieving Q1 rankings in 2023 across multiple categories, including Neurology (clinical), Pharmacology (medical), and Psychiatry and Mental Health. With an impressive Scopus ranking as the 11th of 272 in medical pharmacology and high percentiles in psychiatry and neurology, it fosters high-quality research publication and dissemination. Spanning over two decades from 1994 to 2024, CNS DRUGS serves as a vital resource for researchers, professionals, and students alike, providing comprehensive insights that drive innovation in clinical practices. Although primarily a subscription-based journal, the richness of its content makes it an essential addition to any institution's library. Striving to bridge the gap between scientific research and clinical application, CNS DRUGS is positioned at the forefront of neurological and psychiatric pharmacotherapy research.

The Journal of the Korean Academy of Child and Adolescent Psychiatry (ISSN: 1225-729X; E-ISSN: 2233-9183) stands as a pivotal resource in the fields of child and adolescent mental health, contributing significantly to the dialogue on psychiatric practices and research in South Korea and beyond. Published by the KOREAN ACADEMY OF CHILD & ADOLESCENT PSYCHIATRY, this journal is recognized for its dedication to advancing the understanding of psychiatric disorders that affect children and adolescents, as evidenced by its Q3 ranking in both Pediatrics, Perinatology and Child Health and Psychiatry and Mental Health categories for 2023. Operated from Seoul, South Korea, the journal facilitates knowledge-sharing among researchers and practitioners, providing insights into clinical practices and innovative treatment methodologies. Although not openly accessible, the journal emphasizes quality over quantity in its selection of studies, making each article a valuable contribution to the field. As the journal continues to publish impactful research through 2024, it remains essential reading for those committed to the well-being of younger populations and their families.

JOURNAL OF PSYCHOPHARMACOLOGY, published by SAGE Publications Ltd, is a leading peer-reviewed journal that explores the intricate dynamics of pharmacological interventions in mental health and psychiatry. With an ISSN of 0269-8811 and an E-ISSN of 1461-7285, this esteemed journal has established its reputation in the field since its inception in 1987, converging research excellence into 2024. Recognized as a Q1 journal in various categories including Medicine (miscellaneous), Pharmacology, and Psychiatry and Mental Health, it ranks impressively within the top percentile in Scopus, standing at #64 out of 567 in Psychiatry and Mental Health, and #31 out of 272 in Medical Pharmacology. The journal serves as a vital resource for researchers, professionals, and students, providing insightful articles that advance the understanding of psychopharmacological effects and innovations. Although it does not offer open access, the journal's extensive research and impactful findings make it essential reading for anyone engaged in the field. For those seeking to stay at the forefront of psychopharmacology, the JOURNAL OF PSYCHOPHARMACOLOGY is an invaluable asset.

BJPsych Open, published by Cambridge University Press, is a leading open access journal dedicated to the field of psychiatry and mental health. Since its inception in 2015, the journal has provided a platform for disseminating cutting-edge research and evidence-based practices, making significant contributions to the academic community. With an impressive impact factor and currently ranking in the top Q1 quartile of its field, BJPsych Open is recognized for its rigor and relevance, ranking 138 out of 567 journals in psychiatry and mental health according to Scopus, placing it in the 75th percentile. The journal's commitment to open access enhances visibility and accessibility, ensuring that vital research is available to a global audience. Researchers, professionals, and students alike will find valuable insights into contemporary mental health challenges and innovative treatment approaches, making BJPsych Open an essential resource for advancing mental health scholarship.